Letter to the Editor: Salidroside in ulcerative colitis - neuroimmune regulatory mechanisms and clinical translation prospects

Key Takeaways for GI Nurses

• Salidroside, a natural bioactive compound, is being investigated as a complementary therapeutic option for ulcerative colitis (UC), working through a novel mechanism involving the cAMP-PKA-CREB signaling pathway rather than traditional immunosuppression.
• This research highlights the emerging "enteric neuro-glial-immune network" — a reminder that UC pathophysiology extends beyond mucosal inflammation to include enteric glial cell (EGC) activation, which nurses should understand when educating patients about disease complexity.
• Current first-line UC therapies (5-ASA, corticosteroids, immunosuppressants) carry significant long-term limitations including steroid dependence, infection risk, and drug resistance — reinforcing why patients often ask about alternative or adjunct therapies during clinic visits and infusion appointments.
• While still preclinical/early-stage, salidroside's anti-inflammatory, antioxidant, and mucosal barrier-repair properties position it as a potential future adjunct therapy, making this a topic worth monitoring for patient education and journal club discussions.

Clinical Relevance

For GI nurses managing UC patients across outpatient infusion suites, endoscopy units, and inflammatory bowel disease (IBD) clinics, this editorial underscores a critical clinical reality: despite effective first-line therapies, many patients struggle with sustained remission due to steroid dependence, opportunistic infections, and treatment resistance. Nurses frequently serve as the primary point of contact when patients express frustration with these limitations or ask about complementary and alternative approaches. Understanding that researchers are actively exploring compounds like salidroside — which targets the gut-brain axis through enteric glial cell modulation rather than broad immunosuppression — equips nurses to have more informed conversations with patients about the evolving UC treatment landscape, while appropriately framing this as investigational research rather than an approved therapy.

The concept of enteric glial cells and the neuro-immune regulatory network is increasingly relevant to bedside and clinic-based nursing assessment. EGCs are now recognized as key players in intestinal barrier integrity and inflammatory signaling, not merely as mechanical reactive. For nurses performing symptom assessments, documenting flare patterns, or triaging patient-reported outcomes (urgency, pain, stress-related symptom flares), this research reinforces the biological plausibility of the gut-brain connection that many UC patients describe anecdotally — particularly stress-triggered exacerbations. This knowledge can enhance patient education around stress management, sleep, and lifestyle factors as adjuncts to pharmacologic therapy.

From a professional development standpoint, this letter exemplifies the kind of translational research nurses should track as IBD management evolves toward more targeted, mechanism-specific therapies. As natural compounds and novel signaling pathways move from bench to bedside, endoscopy and infusion nurses will increasingly need to understand mechanisms beyond standard pharmacology to answer patient questions, participate in clinical trial recruitment, and contribute meaningfully to multidisciplinary IBD care teams.

Bottom Line

While salidroside remains an investigational compound rather than a clinical treatment option, this editorial signals an important shift in UC research toward neuro-glial-immune mechanisms and mucosal barrier repair — knowledge that GI nurses can use now to better contextualize patient questions about treatment limitations and emerging therapies, while staying alert for future clinical trial developments in this space.